ParameswaranNHariMD

Oncology • Milwaukee, WI

Hematologic Oncology

MCW

Join to view full profile

Dr. Hari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hari's full profile

Already have an account?

Office
9200 W Wisconsin Ave
# Hematolo
Milwaukee, WI 53226
Phone+1 414-805-0505

Fax+1 414-805-4606

Summary

Dr. Parameswaran Hari is an oncologist based in Milwaukee, WI, specializing in hematologic oncology. He completed his residency in internal medicine at Main Line Health System/Lankenau Medical Center and his fellowship in hematology and medical oncology at the Medical College of Wisconsin Affiliated Hospitals. Dr. Hari has expertise in metabolic syndrome, cardiac graft versus host disease, amyloidosis, and myelodysplasia. He has numerous publications in esteemed journals such as The New England Journal of Medicine and the Journal of Clinical Oncology, and he participates in various clinical trials focused on multiple myeloma and hemophilia. Dr. Hari has received recognition as a Regional Top Doctor and holds a CMS Meaningful Use Stage 1 Certification.

Education & Training

Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2002 - 2004
Main Line Health System/Lankenau Medical CenterResidency, Internal Medicine, 1991 - 1994
University of Kerala Medical CollegeClass of 1992

Certifications & Licensure

WI State Medical License 2002 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
Completed
Phase 2
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 1, Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Nov 01
Completed
Phase 3
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation Start of enrollment: 2015 Jun 01
Completed
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2015 Oct 09
Completed
Phase 1, Phase 2
Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation Start of enrollment: 2016 Nov 01
Completed
Phase 2
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma Start of enrollment: 2017 Jul 25
Recruiting
Tinostamustine Conditioning and Autologous Stem Cell Start of enrollment: 2018 Oct 15
Terminated
Phase 1, Phase 2
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia a Start of enrollment: 2020 Apr 29
RECRUITING
PHASE1
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Start of enrollment: 2019 Aug 13
RECRUITING
PHASE3
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Start of enrollment: 2019 Sep 23
Active, not recruiting
Phase 1
A Study of WVT078 in Patients With Multiple Myeloma (MM) Start of enrollment: 2019 Dec 05
TERMINATED
PHASE1
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2020 Nov 30
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19.
Wen Zhu, Yongwei Zheng, Mei Yu, Nathan Witman, Lu Zhou
Blood. 2025-02-06
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.
Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence G Lum
Journal for Immunotherapy of Cancer. 2025-01-28
Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History.
Mary Eapen, Lynn M Malec, Myriam A Armant, Bryon D Johnson, Qizhen Shi
The New England Journal of Medicine. 2025-01-23

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma
Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
Second Primary Malignancy After Multiple Myeloma‐Population Trends and Cause‐Specific Mortality
Parameswaran Hari, Luciano J Costa, Saurabh Chhabra, Kelly N Godby, British Journal of Haematology
Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...
Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature
Join now to see all

Abstracts/Posters

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Mu...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Lo...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...
Parameswaran Hari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A 3D Learning Experience: Novel Combination Treatment Options and Sequencing Strategies for Personalized Management of Relapsed and/or Refractory Multiple Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).
2019 ASCO Annual Meeting - 6/1/2019
Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a No...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Interprofessional Collaboration Examples and How to Implement ItDecember 2nd, 2023
New FDA Approved Drug for Multiple MyelomaMarch 25th, 2021
Hem/Onc Roundup: Financial Toxicity in MM Treatment, Personalizing Cancer Care, and MoreFebruary 19th, 2021
Join now to see all